Key result
CIEDs remain essential for preventing sudden cardiac death and managing advanced heart failure.
Why the study?
A growing heart failure population presents significant clinical challenges in managing cardiac arrhythmias and advanced heart failure syndromes, where device therapy has become essential.
Does cardiac implantable electronic device therapy reduce sudden cardiac death and all-cause mortality in patients with heart failure?
Does cardiac implantable electronic device therapy reduce sudden cardiac death and all-cause mortality in patients with heart failure?
This review highlights the established role of ICDs in preventing sudden cardiac death in heart failure, while noting evolving debates regarding their mortality benefit in nonischemic cardiomyopathy on modern medical therapy.
Supports CIED role in HF/SCD prevention; leaves open mortality benefit questions in nonischemic cardiomyopathy on modern GDMT.
The population of patients with heart failure continues to grow, which introduced significant challenges in clinical practice related to the management of cardiac arrhythmia and advanced heart failure syndromes. Device therapy has increasingly become essential in the management of life-threatening arrhythmia and clinical heart failure in this population. This review will discuss the use of cardiac implantable electronic devices in heart failure with primary focus on sudden cardiac death prevention and cardiac resynchronization, including published evidence and evolving technologies.
No takes yet. Share an insight, caveat, or question.
Hussein et al. (2019) studied this question. Cardiac implantable electronic devices are essential for preventing sudden cardiac death and managing advanced heart failure in the growing population of heart failure patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: